198 related articles for article (PubMed ID: 29112524)
1. Dermoscopic Guidance of Talimogene Laherparepvec Injection for Metastatic Melanoma.
Khalsa A; Bacik L; Pameijer C; Seiverling E
Dermatol Surg; 2018 Jul; 44(7):1026-1028. PubMed ID: 29112524
[No Abstract] [Full Text] [Related]
2. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
4. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
Garnock-Jones KP
BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
[TBL] [Abstract][Full Text] [Related]
5. Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab.
Naqash AR; Stroud G; Collichio FA; Muzaffar M; Sharma N; Walker P
Acta Oncol; 2017 Oct; 56(10):1327-1330. PubMed ID: 28481677
[No Abstract] [Full Text] [Related]
6. Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response.
Iglesias P; Ribero S; Barreiro A; Podlipnik S; Carrera C; Malvehy J; Puig S
Acta Derm Venereol; 2019 Feb; 99(2):232-233. PubMed ID: 30281140
[No Abstract] [Full Text] [Related]
7. Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
Ott PA; Hodi FS
Clin Cancer Res; 2016 Jul; 22(13):3127-31. PubMed ID: 27146699
[TBL] [Abstract][Full Text] [Related]
8. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virus immunotherapy for melanoma.
Dharmadhikari N; Mehnert JM; Kaufman HL
Curr Treat Options Oncol; 2015 Mar; 16(3):326. PubMed ID: 25777572
[TBL] [Abstract][Full Text] [Related]
11. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
12. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
Andtbacka RH; Ross M; Puzanov I; Milhem M; Collichio F; Delman KA; Amatruda T; Zager JS; Cranmer L; Hsueh E; Chen L; Shilkrut M; Kaufman HL
Ann Surg Oncol; 2016 Dec; 23(13):4169-4177. PubMed ID: 27342831
[TBL] [Abstract][Full Text] [Related]
13. Talimogene laherparepvec (Imlygic) for unresectable melanoma.
Med Lett Drugs Ther; 2016 Jan; 58(1486):8-9. PubMed ID: 26761342
[No Abstract] [Full Text] [Related]
14. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
15. NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma.
Adam J; Robertson J; Donegan E; Voicechovskaja I
Lancet Oncol; 2016 Nov; 17(11):1485-1486. PubMed ID: 27692478
[No Abstract] [Full Text] [Related]
16. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F
Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413
[TBL] [Abstract][Full Text] [Related]
17. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Dummer R; Hoeller C; Gruter IP; Michielin O
Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
Burke EE; Zager JS
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
[TBL] [Abstract][Full Text] [Related]
19. Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.
Miller DM; Trowbridge RM; Desai A; Drews RE
J Immunother Cancer; 2018 Nov; 6(1):122. PubMed ID: 30454071
[TBL] [Abstract][Full Text] [Related]
20. Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
Hoffner B; Iodice GM; Gasal E
Oncol Nurs Forum; 2016 Mar; 43(2):219-26. PubMed ID: 26906132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
